News >

Ipilimumab Approaches EU Approval for Pediatric Melanoma

Jason M. Broderick @jasoncology
Published: Monday, Dec 18, 2017

Murdo Gordon, BMS executive vice president and chief commercial officer

Murdo Gordon
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of ipilimumab (Yervoy) for the treatment of pediatric patients aged 12 years and older with unresectable or metastatic melanoma, according to Bristol-Myers Squibb (BMS), the manufacturer of the CTLA-4 inhibitor.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication